May 21, 2014
LOS ANGELES, May 21, 2014 /PRNewswire/ -- Research Solutions, Inc. (OTC-BB: RSSS), a pioneer in facilitating the flow of information from the publishers of scientific, technical, and medical content to enterprise customers in Life Sciences and other research intensive organizations around the world, today announced that Valeant Pharmaceuticals had adopted Bibliogo, the literature management and collaboration web application add-on for the company's Article Galaxy software-as-a-service (SaaS) solution. Valeant Pharmaceuticals will utilize Bibliogo, winner of the 2012 Software & Information Industry (SIIA) CODiE Award for Best Online Science or Technology Service, to support drug safety monitoring and other literature-related medical affairs functions within the Latin America office.
"Bibliogo will help the Medical Affairs team at Valeant Pharmaceuticals to better acquire, manage and collaborate securely around the scientific literature that my team relies upon to support our internal and external customers," said Gerardo Gutierrez, Scientific Librarian at Valeant Pharmaceuticals. "Bibliogo meets our specific needs for a collaborative, web-based reference management tool with permission schemas designed for use by corporations, complemented by additional functionality such as document delivery literature retrieval and integrated table of contents and saved search alerting."
For more information about Research Solutions, visit www.researchsolutions.com. Visit www.reprintsdesk.com for more information about Reprints Desk or www.bibliogo.com for more information about Bibliogo.
About Research Solutions®
Research Solutions, Inc. is a pioneer in facilitating the flow of information from the publishers of scientific, technical, and medical content to enterprise customers in life science and other research intensive organizations around the world. We develop products, services and systems to facilitate the re-use of published content in a manner that helps organizations achieve their research, marketing, and communication goals effectively and in compliance with copyright law and regulatory rules. Our subsidiary companies include Reprints Desk, Inc., and Techniques Appliquees aux Arts Graphiques, S.p.A. (TAAG). For more information, please visit www.researchsolutions.com.
About Reprints Desk®
Reprints Desk improves how journal articles and clinical reprints are accessed, procured, and legally used in evidence-based promotions, medical affairs, and scientific, technical, and medical (STM) research. Organizations fueled by intellectual property (IP) choose Reprints Desk because of its collaborative business approach, efficient article supply system and services, and commitment to quality post-sales support. Reprints Desk has ranked #1 in the every Document Delivery Vendor Scorecard from industry analyst and advisory firm Outsell Inc. since 2008.
Certain matters discussed in this press release may be forward-looking statements. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in obtaining new customers; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; the Company's success in integrating acquired entities and assets, and all the risks and related information described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"), including the financial statements and related information contained in the Company's Annual Report on Form 10-K and interim Quarterly Reports on Form 10-Q. Examples of forward-looking statements in this release include statements related the Company's products. The Company assumes no obligation to update the cautionary information in this release.
SOURCE Research Solutions, Inc.
For further information: Ian Palmer, Chief Sales and Marketing Officer, Research Solutions, Inc., P: +1 (415) 533-8308, E: [email protected]